Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Becker

Gastroenterology Clearwater, FL Medical Doctor

NPI 1629151477 CMS profile 301117

508 Jeffords St, Suite D, Clearwater, FL 33756

Open in the dashboard

General payments

$6,716

325 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$9,764 paid to institutions, not to them · program years 2019–2021

Through program year 2025, David Becker of Clearwater, FL is reported in the CMS Open Payments database as having received $6,716 across 325 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $9,764 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 73rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,662 64
2024 General $1,276 52
2023 General $1,637 88
2022 General $716 44
2021 General $299 16
2020 General $334 18
2019 General $790 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Becker
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to David Becker were reported at $1,662. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year David Becker Gastroenterology median Middle half National median
2019 $790 $417 $126–$1,100 $163
2020 $334 $224 $74–$624 $114
2021 $299 $352 $106–$1,054 $132
2022 $716 $448 $129–$1,270 $149
2023 $1,637 $533 $150–$1,390 $160
2024 $1,276 $605 $160–$1,606 $164
2025 $1,662 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,606 94 payments
  2. Janssen Biotech, Inc. $1,103 52 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $851 45 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $444 29 payments
  5. Gilead Sciences, Inc. $335 15 payments
  6. Madrigal Pharmaceuticals $310 8 payments
  7. Pfizer Inc. $300 14 payments
  8. Celgene Corporation $190 9 payments
  9. Phathom Pharmaceuticals, Inc. $186 3 payments
  10. Celltrion USA Inc. $173 6 payments
  11. Other $1,216 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,571 319 payments
  2. Education $131 5 payments
  3. Entertainment $14 1 payment
Products named General payments · program years 2019–2025
  1. STELARA $881 45 payments
  2. RINVOQ $645 39 payments
  3. CREON $580 35 payments
  4. SIMPONI $497 25 payments
  5. ENTYVIO $489 21 payments
  6. SIMPONI ARIA $463 23 payments
  7. SKYRIZI $424 23 payments
  8. XIFAXAN $420 27 payments
  9. LINZESS $366 19 payments
  10. TREMFYA $356 12 payments
  11. Other $3,912 177 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

824

Median for Gastroenterology: 569

Drug cost

$88,818

Median for Gastroenterology: $104,976

Branded share of claims

40.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 12 $12,581
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 72 $12,439
Fluticasone Propionate Hfa Fluticasone Propionate Brand 15 $10,934
Voquezna Vonoprazan Fumarate Brand 14 $8,761
Trulance Plecanatide Brand 12 $6,739
Mesalamine Generic 15 $6,311
Alosetron Hcl Generic 13 $3,914
Dexlansoprazole Dr Dexlansoprazole Brand 12 $3,164
Pantoprazole Sodium Generic 191 $2,481
Cholestyramine Light Cholestyramine Brand 20 $2,345

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$116,295

Medicare's payments for the services billed

Medicare patients

260

Average age 75

Services billed

3,898

148 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 57%
Ischemic heart disease 35%
Chronic kidney disease 30%
Depression 28%
Diabetes 25%
Osteoporosis 21%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $160
$160 14 —
CREON
  • AbbVie, Inc. $132
$132 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $112
$112 — —
TREMFYA
  • Janssen Biotech, Inc. $105
$105 — —
SKYRIZI
  • AbbVie, Inc. $98
$98 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record